Background: The association between type 2 diabetes and hospital outcomes of sepsis remains controversial when severity of diabetes is not taken into consideration. We examined this association using nationwide and hospital-based databases. Methods: The first part of this study was mainly conducted using a nationwide database, which included 1.6 million type 2 diabetic patients. The diabetic complication burden was evaluated using the adapted Diabetes Complications Severity Index score (aDCSI score). In the second part, we used laboratory data from a distinct hospital-based database to make comparisons using regression analyses. Results: The nationwide study included 19,719 type 2 diabetic sepsis patients and an equal number of nondiabetic sepsis patients. The diabetic sepsis patients had an increased odds ratio (OR) of 1.14 (95% confidence interval 1.1-1.19) for hospital mortality. The OR for mortality increased as the complication burden increased [aDCSI scores of 0, 1, 2, 3, 4, and ⩾5 with ORs of 0.91, 0.87, 1.14, 1.25, 1.56, and 1.77 for mortality, respectively (all p < 0.001)]. The hospital-based database included 1054 diabetic sepsis patients. Initial blood glucose levels did not differ significantly between the surviving and deceased diabetic sepsis patients: 273.9 ± 180.3 versus 266.1 ± 200.2 mg/dl (p = 0.095). Moreover, the surviving diabetic sepsis patients did not have lower glycated hemoglobin (HbA1c; %) values than the deceased patients: 8.4 ± 2.6 versus 8.0 ± 2.5 (p = 0.078). Conclusions: For type 2 diabetic sepsis patients, the diabetes-related complication burden was the major determinant of hospital mortality rather than diabetes per se, HbA1c level, or initial blood glucose level.
Introduction
Sepsis is a leading cause of mortality in critical care worldwide. [1] [2] [3] In addition to mortality, sepsis may also cause long-term postsepsis cardiovascular disease. 4 The reported incidence of sepsis varies; however, an undoubtedly increasing trend has been reported, reflecting the aging population and greater recognition of this condition. Furthermore, treating sepsis patients creates a significant national financial burden.
Diabetes is an important comorbid condition in sepsis because of its high prevalence. 5 Diabetic patients are generally believed to be more prone to infections than the general population. 6 However, the influence of diabetes on the outcome of sepsis remains inconclusive. Higher mortality rates in patients with diabetes have been reported; [7] [8] [9] [10] [11] [12] however, other studies have found no effect of diabetes [13] [14] [15] [16] or even protective effects of diabetes on sepsis. [17] [18] [19] [20] Within this debate, the most frequently proposed study limitation was study design. Epidemiological studies using large cohorts can avoid the selection bias that is frequently observed in hospital-based studies, but detailed clinical information is usually not available. Most importantly, many studies have failed to consider the influence of diabetic complication severity.
Hemoglobin A1C (HbA1c) is commonly used to measure blood glucose control in diabetic patients and has also been proposed as an independent predictor of hospital mortality in sepsis patients. 21 However, its importance in diabetic sepsis patients requires further study because of limited data. Hyperglycemia has been shown to impair polymorphonuclear neutrophil function and cytokine production. However, high initial glucose levels were not reported to be associated with increased mortality in diabetic sepsis patients. 22 Furthermore, tight glucose control did not seem to be significantly associated with reduced hospital mortality in critical patients. 23, 24 The influences of HbA1c and initial glucose levels on the outcome of sepsis deserve further investigation.
In the current study, using a representative nationwide database and a hospital-based database from multiple centers with laboratory data, we examined the association between type 2 diabetes and sepsis outcomes, specifically focusing on (a) whether type 2 diabetes itself increases the risk of mortality in hospitalized sepsis patients or whether risk of mortality depends on diabetic complication burdens, and (b) whether initial blood glucose level and HbA1c affect the hospital outcome.
Methods

Data sources and study participants
In this study, we used two distinct databases: Because the hospital-based database lacked longitudinal information for each type 2 diabetic individual, we used the LHDB and LHID 2000 to resolve this limitation. The LHDB and LHID 2000 recorded all the medical information for each individual, such as outpatient (at clinics or hospitals) and emergency department visits (at every hospital) and hospitalizations that were not limited to a single medical facility. Therefore, data from the NHIRD avoided recall bias and could be used in the longitudinal cohort study.
In contrast, the hospital-based database from multiple centers could provide laboratory data, such as HbA1c, initial blood glucose level, and culture results. However, the information was restricted to a single facility, and important information from other clinics or hospitals might be missed.
Nationwide database
In the first part of this study, we conducted a nationwide cohort study using data from the NHIRD. The diagnosis codes of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) are used in the NHIRD to identify specific diagnoses. Data for sepsis patients were retrieved using the ICD-9-CM code 038 plus a main infection diagnosis with antibiotics prescription. The accuracy of sepsis diagnosis in the NHIRD has been validated in previous studies. 25 The infection site classification was conducted following the criteria developed by Angus and colleagues. 26 The patients were classified as using certain drugs if they took the drugs for more than 1 month within a 1-year period prior to the index hospitalization (the first admission for sepsis). The index date was defined as the first day of index hospitalization. The drugs, procedures, special modalities, intensive care unit (ICU) admission, and length of hospital stay were recorded using the claims data of the NHIRD.
Initially, we used the LHDB of the NHIRD, which contains randomized selected data (a total of 1.68 million enrollees from 1999 to 2012) from patients with newly diagnosed diabetes to journals.sagepub.com/home/tae 3 retrieve the study cohort of type 2 diabetic firstepisode sepsis patients. 27 The patients in the study cohort had to have been diagnosed with type 2 diabetes at least 1 year prior to the index hospitalization to allow for the evaluation of diabetic complication burden by using the adjusted Diabetes Complications Severity Index score (aDCSI score). 28, 29 The Diabetes Complications Severity Index (DCSI) was first developed by Young and coworkers. 28 The DCSI is a useful tool for adjusting for the baseline severity of diabetic complications and predicting hospital mortality. The aDCSI score was modified from the DCSI score and had been validated in the NHIRD. 30 The aDCSI score included seven categories of complications: cardiovascular disease, nephropathy, neuropathy, retinopathy, peripheral vascular disease, stroke, and metabolic emergency events. The selection process of participants from the nationwide and hospital-based databases is shown in Supplement Figure 1 . Most of the enrolled type 2 diabetic sepsis patients in the hospital database from multiple centers could be traced and linked to the nationwide database by a specific matching method. 31 However, matching was not allowed in Taiwan at the time of this study. Regarding the data in the hospitalbased database, initial blood glucose levels were measured on the day of admission, either in the emergency department or on the ward, before patients received any acute glucose-lowering injection therapy (i.e. insulin). HbA1c levels were assessed during a 1-month period prior to the admission day.
Statistical analyses. Differences in demographic characteristics, comorbidities, medications, and laboratory data were examined using the chisquare test, the Mann-Whitney test and a twosample t test. Odds ratios (ORs) with 95% confidence intervals (95% CIs) were calculated using a logistic regression model. A Kaplan-Meier analysis with the log-rank test was performed to compare hospital outcomes among type 2 diabetic sepsis patients with different initial blood glucose levels and HbA1c values. Statistical analyses were performed using the SAS 9.4 statistical package (SAS Institute Inc., Cary, NC, USA). A p value of 0.05 was considered indicative of significance.
Results
First part: nationwide database
After propensity-score matching, data collected between 1999 and 2012 for 19,719 type 2 diabetic first-episode sepsis patients and an equal number of nondiabetic first-episode sepsis patients were retrieved as the study and comparison cohorts from the LHDB and LHID 2000. Demographic characteristics, comorbidities, medications, infection sites, and received procedures of the study and comparison cohorts are shown in Table 1 . Table 3 ). Furthermore, the type 2 diabetic sepsis patients had a higher ICU admission rate (57.5% versus 55.3%, p = 0.249) and acute physiologic and chronic health II (APACH II) score (25.3 ± 7.1 versus 24.9 ± 7.0, p = 0.292) than the nondiabetic sepsis patients, although the p value did not reach significance. Accordingly, the type 2 diabetic sepsis patients had a higher hospital mortality rate (45.2% versus 42.3%, p = 0.138) and 28-day mortality rate (35.5% versus 32.8%, p = 0.147) than the nondiabetic sepsis patients. The type 2 diabetic sepsis patients had a higher prevalence of Gram-positive coccus bacteremia (16.8% versus 14.4%, p = 0.089) but a lower prevalence of Gram-negative bacillus bacteremia (19.1% versus 20.7%, p = 0.294) than the nondiabetic sepsis patients.
In the univariate and multivariate logistic regression analyses, type 2 diabetes was associated with an increased risk of hospital mortality during the sepsis course (adjusted OR = 1.31, 95% CI 1.11-1.54, p = 0.002). This result was similar to that obtained for the nationwide database. The Kaplan-Meier analysis with log-rank test also showed a difference in hospital mortality between the type 2 diabetic and nondiabetic sepsis patients [p = 0.122; Figure 1(a) ].
The 1054 type 2 diabetic sepsis patients were divided into two groups, surviving and deceased patients, for further comparison. Initial blood glucose levels between the surviving and deceased diabetic sepsis patient groups did not differ significantly: 273.9 ± 180.3 versus 266.1 ± 200.2 [mg/dl; p = 0.095; Figure 1(b) ]. Furthermore, the surviving diabetic sepsis patients did not have lower HbA1c (%) levels than the deceased diabetic sepsis patients: 8.4 ± 2.6 versus 8.0 ± 2.5 (p = 0.078; Supplement Table 2 ). The univariate analysis, another logistic regression analysis that included age, sex, Charlson comorbidity index score, and important laboratory data, showed an OR of 1.00 (95% CI 1.00-1.00, p = 0.532) for initial glucose levels and 0.94 (95% CI 0.86-1.02, p = 0.143) for HbA1c. The Kaplan-Meier analysis with log-rank test also showed that hospital mortality did not differ among type 2 diabetic sepsis patients with different initial blood glucose levels (⩽200, 201-400, and >400 mg/dl) and HbA1c values (⩽7 and >7%) [ Figure 2 (a) and (b)].
Sensitivity analysis
We analyzed multiple models adjusted for drugs, procedures, and infection sites to examine the stability of the main model, that is, the multivariate analysis based on the aDCSI score. The models showed that the hospital mortality rate of sepsis increased as the aDCSI score increased (Supplement Table 3 ).
In the sensitivity analysis, we used a stricter inclusion criterion for HbA1c collection: the HbA1c needed to be collected within 3 days of admission. A total of 366 (sample size reduced from 953 to 366) type 2 diabetic sepsis patients were included.
The difference in hospital mortality rate remained unchanged (a hospital mortality rate of 39.5% for HbA1c ⩽ 7 and 35.2% for HbA1c > 7). In addition, we conducted another sensitivity analysis that excluded the outlier subjects with initial blood sugar levels > 600 or <50 mg/dl. The study results remained unchanged (for initial blood glucose levels ⩽200, 201-400, and >400 mg/dl, the hospital mortality rates were 48.2%, 41.2%, and 48.1%, respectively, p = 0.136).
Discussion
In this study, we demonstrated that the outcome of type 2 diabetic sepsis patients was mainly determined by the cumulative diabetic complication burden (represented by the aDCSI score) rather than diabetes itself. The above argument was reinforced by the reverse ORs found in the type 2 diabetic sepsis patients with an aDCSI score ⩽ 1. In other words, if type 2 diabetic patients have few complications, they may not have an inferior hospital outcome of sepsis compared with nondiabetic patients. Furthermore, somewhat surprisingly, neither recent glucose control (HbA1c) nor the initial blood glucose level was associated with hospital mortality during the sepsis course. In conclusion, clinicians should not infer the outcome of a type 2 diabetic sepsis patient merely on the basis of recent glucose control or initial glucose level; rather, they should consider the cumulative diabetic complication burden. The stereotype of the impact of type 2 diabetes in sepsis should be modified.
This study contributes at least two important novelties in clinical practice. First, we described the trajectory of type 2 diabetic sepsis patients from the past (cumulative diabetic complication burdens) to the recent past (blood glucose control within the prior 3 months, HbA1c) and the present (initial blood glucose at admission). The connections were bridged by using the nationwide diabetic patient database and the multicenter hospital databases concurrently. Second, we evaluated the severity of type 2 diabetic patients by using the aDCSI score, which is specific for the evaluation of diabetic complication burdens, and we explored its use in sepsis outcome predictions.
Donnelly and colleagues demonstrated that diabetes was associated with an increased risk of hospitalization due to infectious diseases. However, diabetes itself and insulin use were not associated with increased 28-day hospital mortality. 32 Nonetheless, Dianna and coworkers demonstrated that patients with diabetes had an excess risk of dying from a range of infectious diseases. 33 Both studies used a large cohort, but their conclusions were conflicting. We infer that the difference was due to the lack of a classification of diabetes severity. In our study, we introduced the use of the aDCSI score, and the results showed that the sepsis outcomes of diabetic patients were mainly determined by the complication burden of HbA1c is a widely used marker that reflects the average glucose level within the previous 120 days. Furthermore, HbA1c was reported a major outcome predictor in diabetic sepsis patients. 21 However, our study results did not support this argument. Many studies support the influence of long-term glycemic control on diabetic complication development. 34, 35 Poor long-term glycemic control makes diabetic patients prone to infectious diseases because of their impaired immune functions. 32 In this study, HbA1c levels were assessed during a 1-month period prior to the admission day. In Taiwan, because of the convenience and high quality of medical care, the diabetes specialists were easily accessed without the need of long waiting. Patients could receive antidiabetic drug adjustment according to the HbA1c level in the outpatient department on time. Furthermore, the diabetic sepsis patients presenting with higher HbA1c levels may receive more aggressive blood sugar control with insulin in the initial stage of sepsis. Although, the hospital outcome of diabetic sepsis patients with higher HbA1c was not be as poor as initially thought, more evidence was needed to document this result.
Hyperglycemia frequently occurs in sepsis patients as a stress response that stimulates gluconeogenesis, which uses recycled pyruvate and lactate. [36] [37] [38] Hyperglycemia may have protective effects in patients because high blood glucose levels increase the diffusion gradient in tissues with abnormal microvasculature caused by sepsis. Our study may indirectly support the above argument. A study by van Vught and colleagues demonstrated that admission hyperglycemia was associated with adverse outcomes in sepsis, irrespective of the presence of diabetes. 39 However, our study demonstrated that a high blood glucose level at admission was not associated with hospital outcome. We inferred that the initial blood glucose level was an important risk factor for mortality in nondiabetic sepsis patients but not in type 2 diabetic sepsis patients.
Our study has the following strengths. In the study of the nationwide database, we used claims data for procedures such as mechanical ventilation, hemodialysis, and blood transfusion. The accuracy of this approach is far superior to using only ICD-9 or 10 codes for acute organ dysfunction. Furthermore, detailed information, such as blood culture results and APACH II scores, in the hospital-based database provided a richer understanding of the complex interplay between type 2 diabetes and sepsis, rather than simple taxonomy.
This study is not without limitations. We were able to link the individual patient's medical information between the hospital-based database and the nationwide diabetic patient database to create a convincing longitudinal cohort study. However, due to the increasing conflict surrounding healthcare database use in Taiwan, we abandoned this idea to avoid further severe debates. Second, some may challenge our use of a previous sepsis definition, originating from the systemic inflammatory response syndrome (SIRS) criteria, rather than the sepsis-3 definition. However, we believe that the central idea of this study would not change. We retrieved the study cohort by using ICD-9 codes not only for sepsis (038) but also for main infection origins, such as pneumonia or biliary tract infection. Therefore, we are confident that all the retrieved sepsis patients in our study were truly infected and did not have other conditions, such as pancreatitis, burn injury, or trauma, which would similarly induce SIRS reactions. Furthermore, as noted by Cortes-Puch I and coworkers, 'Moreover, these previous definitions and the SIRS criteria have been widely adopted for use at the bedside and for hospital and statewide quality improvement initiatives worldwide. Numerous controlled trials have relied on them, and this scientific database should not be discarded until unequivocal evidence indicates that superior diagnostic criteria exist.' 40 We believe that our study could still provide valuable information to clinicians. Finally, the first sodiumglucose cotransporter-2 (SGLT2) inhibitor (Empagliflozin) was available in Taiwan since 2014. However, our nationwide database only included the data from 1999 to 2012. Therefore, we could not discuss the potential risk of serious urinary tract infections and genital infections in type 2 diabetic patients using SGLT2 inhibitors.
Conclusion
In type 2 diabetic sepsis patients, hospital mortality was mainly determined by the diabetes-related complication burden rather than the diabetes itself. Furthermore, initial blood glucose and HbA1c levels may not be as important as previously thought. Early intervention in type 2 diabetic patients could clearly improve the sepsis outcome, especially in the early stage of diabetes with few diabetic complications.
